Well, it seems a few people on this forum believe that 50:50 is too conservative. So, if I redo the expected value (EV) calculation based on 65:35, with a 5X uplift if successful, then OPT's expected value is $2.24, minus the discount rate of return for a wait time of 1 year and 3 months. Complications arise as Lucentis and Eylea trials are not mutually exclusive; therefore, failure in one is a strong indicator of failure in the other, and of course, success in one will foreshadow success in the other. Success in both could very well result in 8-10X valuation $6.90.
Based on the above from my perspective OPT is a strong speculative buy.
Well, it seems a few people on this forum believe that 50:50 is...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.035(8.54%) |
Mkt cap ! $547.8M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 45.0¢ | 42.0¢ | $3.084M | 7.074M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 192000 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |